Today: 9 June 2026
Circle (CRCL) stock slips today as bitcoin heads for first annual loss since 2022
31 December 2025
2 mins read

Circle (CRCL) stock slips today as bitcoin heads for first annual loss since 2022

NEW YORK, December 31, 2025, 15:54 ET — Regular session

  • Circle shares fell about 1% in late-afternoon trade on the final session of 2025.
  • Bitcoin was lower and on track for its first annual decline since 2022, weighing on crypto-linked equities.
  • Traders are watching year-end funding conditions and the 2026 rate path that influences yields on reserve assets.

Circle Internet Group, Inc. shares slipped in afternoon trading on Wednesday, tracking a softer tone across crypto-linked assets into the final hour of the year’s last U.S. session. The stock was down 1.1% at $79.05, after trading between $78.98 and $80.37.

The move matters because Circle sits at the intersection of two markets that have been volatile into year-end: cryptocurrencies and short-term U.S. rates. Both can move quickly around thin liquidity and policy headlines.

Circle issues USDC, a so-called stablecoin — a crypto token designed to keep a steady value — and stablecoins are typically backed by low-risk assets such as U.S. dollars and Treasury bonds, a Reuters report on the company’s IPO filing said. USDC is the second-biggest stablecoin after Tether, according to CoinGecko, the report said.

Bitcoin was on track to end 2025 down more than 6% — its first annual loss since 2022 — after a year in which it hit a record above $126,000 in October and then struggled to regain footing, a separate Reuters report said. “Bitcoin increasingly exhibits the characteristics of a risk asset,” Linh Tran, a senior market analyst at XS.com, said. Reuters

Bitcoin was down 0.4% at about $87,513 in the latest trade.

Other crypto-exposed names fell more sharply. Coinbase Global was down 2.2%, while Strategy — a prominent bitcoin holder — slid 2.5%.

Rates were also in focus into year-end. U.S. short-term funding markets saw the usual turn-of-year tension, but Federal Reserve bill-buying and a record $74.6 billion draw on the New York Fed’s Standing Repo Facility helped keep cash moving through the system, market participants told Reuters.

Bond investors are heading into 2026 expecting the Fed to slow the pace of rate cuts after easing by 75 basis points in 2025, with traders pricing about 60 basis points of easing next year as of Monday, Reuters reported. For companies whose economics are tied to yields on short-dated government securities, the direction of policy expectations can matter as much as crypto prices.

Circle went public in June after pricing its U.S. initial public offering at $31 a share, raising $1.05 billion, Reuters reported at the time.

Into the start of 2026, investors will be looking for signs that demand for dollar-pegged tokens remains resilient and that trading and payments activity on crypto rails continues to expand beyond speculative flows.

They will also watch the rate backdrop. Any shift in expectations for Fed cuts — or renewed funding-market stress that pushes short-term borrowing costs higher — can change how investors model the yield earned on reserve assets that underpin stablecoins.

For now, Circle is trading like a macro proxy: sensitive to the daily swing in bitcoin and to how markets are pricing the next leg of U.S. rates.

Stock Market Today

  • Designer Brands (DBI) Beats Q1 Earnings and Revenue Estimates
    June 9, 2026, 10:04 AM EDT. Designer Brands (DBI) reported Q1 earnings of $0.07 per share, surpassing the Zacks estimate of $0.02 and reversing a year-ago loss of $0.26. Revenue hit $696.35 million, just above the $696 million consensus. The company delivered a 250% earnings surprise and has beaten EPS estimates in four consecutive quarters. Shares rose about 19.5% year-to-date, outpacing the S&P 500's 8.2% gain. Despite strong results, the stock holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. The Retail - Apparel and Shoes sector ranks among the top three industries. Future stock performance will depend on management's outlook and upcoming earnings estimate revisions, with current consensus estimates at $0.30 EPS on $744 million revenue next quarter and $0.35 EPS on $2.91 billion revenue for the fiscal year.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop